Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus erythematosus (SLE) and evaluation of SLE genetics in drug repositioning

Yong Fei Wang, Yan Zhang, Zhengwei Zhu, Ting You Wang, David L. Morris, Jiangshan Jane Shen, Huoru Zhang, Hai Feng Pan, Jing Yang, Sen Yang, Dong Qing Ye, Timothy J. Vyse, Yong Cui, Xuejun Zhang, Yujun Sheng, Yu Lung Lau, Wanling Yang

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Objectives Systemic lupus erythematosus (SLE) is a prototype autoimmune disease with a strong genetic component in its pathogenesis. through genome-wide association studies (GWAS), we recently identified 10 novel loci associated with SLE and uncovered a number of suggestive loci requiring further validation. this study aimed to validate those loci in independent cohorts and evaluate the role of SLE genetics in drug repositioning. Methods We conducted GWAS and replication studies involving 12 280 SLE cases and 18 828 controls, and performed fine-mapping analyses to identify likely causal variants within the newly identified loci. We further scanned drug target databases to evaluate the role of SLE genetics in drug repositioning. Results We identified three novel loci that surpassed genome-wide significance, including ST3AGL4 (rs13238909, pmeta=4.40E-08), MFHAS1 (rs2428, pmeta=1.17E-08) and CSNK2A2 (rs2731783, pmeta=1.08E-09). We also confirmed the association of CD226 locus with SLE (rs763361, pmeta=2.45E-08). Fine-mapping and functional analyses indicated that the putative causal variants in CSNK2A2 locus reside in an enhancer and are associated with expression of CSNK2A2 in b-lymphocytes, suggesting a potential mechanism of association. In addition, we demonstrated that SLE risk genes were more likely to be interacting proteins with targets of approved SLE drugs (or=2.41, p=1.50E-03) which supports the role of genetic studies to repurpose drugs approved for other diseases for the treatment of SLE. Conclusion this study identified three novel loci associated with SLE and demonstrated the role of SLE GWAS findings in drug repositioning.

Original languageEnglish (US)
Pages (from-to)1078-1084
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume77
Issue number7
DOIs
StatePublished - Jul 2018
Externally publishedYes

Bibliographical note

Funding Information:
WY, YS and Y-FW received grant support from national Key research and development program of China (2017YFC0909001). WY and YLL received support from research Grant Council of Hong Kong (GrF 17146616, 17125114, HKU783813M). YZ received grant support from national natural Science Foundation of China (Grant no. 81601423). YS, xZ and YC received grant support from national Key basic research program of China (2014Cb541901) and national natural Science Foundation of China (Grant no.81402590).

Funding Information:
Funding WY, YS and Y-FW received grant support from national Key research and development program of China (2017YFC0909001). WY and YLL received support from research Grant Council of Hong Kong (GrF 17146616, 17125114, HKU783813M). YZ received grant support from national natural Science Foundation of China (Grant no. 81601423). YS, xZ and YC received grant support from national Key basic research program of China (2014Cb541901) and national natural Science Foundation of China (Grant no.81402590).

Funding Information:
Acknowledgements the authors thank Hong Kong phd fellowship scheme (HKpF), HKU postgraduate Scholarships and the Edward & Yolanda Wong Fund for supporting postgraduate students who participated in this work.

Publisher Copyright:
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.

Fingerprint

Dive into the research topics of 'Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus erythematosus (SLE) and evaluation of SLE genetics in drug repositioning'. Together they form a unique fingerprint.

Cite this